Netflix Inc. (NASDAQ: NFLX) reported first-quarter financial results after markets closed Monday. The company said that it had $0.64 in earnings per share (EPS) on $3.70 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $0.64 in EPS on $3.69 billion in revenue. The same period of last year had $0.40 in EPS on $2.64 billion in revenue.
During the first quarter, global net adds totaled a new first-quarter record of 7.41 million, up 50% year over year and ahead of the firms 6.35 million forecast. In the United States, Netflix added 1.96 million memberships (compared with a forecast of 1.45 million). Internationally, the firm added 5.46 million memberships.
Note that Netflix now has a total of 125 million total memberships worldwide.
Netflix completed its price adjustment during this past quarter, resulting in 12% average selling price growth for the domestic segment. Another highlight from this report is that the international segment now accounts for 50% of revenue and 55% of memberships.
Top Growth Stocks To Buy Right Now: Curtiss-Wright Corporation(CW)
- [By Stephan Byrd]
Curtiss-Wright (NYSE:CW) declared a quarterly dividend on Wednesday, May 16th, RTT News reports. Shareholders of record on Thursday, June 21st will be paid a dividend of 0.15 per share by the aerospace company on Thursday, July 5th. This represents a $0.60 annualized dividend and a yield of 0.46%.
- [By Max Byerly]
Dynamic Technology Lab Private Ltd decreased its stake in shares of Curtiss-Wright Corp. (NYSE:CW) by 59.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,188 shares of the aerospace company’s stock after selling 4,625 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Curtiss-Wright were worth $430,000 at the end of the most recent quarter.
Top Growth Stocks To Buy Right Now: Yingli Green Energy Holding Company Limited(YGE)
- [By Joseph Griffin]
Yingli Green Energy Holding Co Ltd (NYSE:YGE) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.40 and last traded at $1.53, with a volume of 75280 shares. The stock had previously closed at $1.57.
- [By Logan Wallace]
ValuEngine upgraded shares of Yingli (NYSE:YGE) from a sell rating to a hold rating in a report published on Saturday morning.
Yingli stock opened at $1.60 on Friday. The company has a market capitalization of $30.36 million, a PE ratio of -0.17 and a beta of 1.98. Yingli has a twelve month low of $1.43 and a twelve month high of $2.86. The company has a quick ratio of 0.33, a current ratio of 0.40 and a debt-to-equity ratio of -0.11.
- [By Joseph Griffin]
Yingli Green Energy (NYSE:YGE) had its target price raised by S&P Equity Research from $0.45 to $0.62 in a research report released on Tuesday morning.
- [By Ethan Ryder]
Yingli Green Energy (NYSE: YGE) and Netlist (NASDAQ:NLST) are both small-cap oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
- [By Paul Ausick]
Yingli Green Energy Holding Co. Ltd. (NYSE: YGE) slipped about 1.2% to post a new 52-week low of $1.68 Friday after closing at $1.70 on Thursday. The 52-week high is $3.35. Volume of about 5.9 million was more than 15 times the daily average of around 88,000. The company had no specific news.
Top Growth Stocks To Buy Right Now: Genfit SA (GNFTF)
- [By SEEKINGALPHA.COM]
In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.
- [By ]
This phase 2 data for Madrigal was phenomenal, which is why I think it will do well in a phase 3 trial. The other side of the trade is that Intercept Pharmaceuticals (ICPT) and Genfit (OTCPK:GNFTF) are further along with phase 3 trials, which are expected to read out NASH results by 2019/2020. Intercept has a good drug with Ocaliva, however, it suffers from toxicity issues when Doctors prescribe higher than necessary dosing. On the flip side, Ocaliva has shown a greater difference in fibrosis reduction for NASH in its phase 2 FLINT trial compared to MGL-3196. What do I mean by that? Well, as you can see above MGL-3196 obtained a fibrosis reduction in NASH patients of 29% compared to 23% for those on placebo creating a difference of only 6%. If you look at Ocaliva from the FLINT trial, from Intercept Pharmaceuticals, it had a fibrosis reduction of 35% compared to 19% of those NASH patients on placebo. It is just something to keep in mind. I still believe that MGL-3196 will eventually be approved. The question that should be asked is how well will it do compared to other competitors in the same space with better fibrosis reductions? That will be key, because NASH causes fibrosis (scarring) of the liver. Fibrosis eventually turns into cirrhosis of the liver, which can eventually lead to liver failure. That’s why, in my opinion, a drug that will have the most impact on NASH will be one that shows a major reduction in fibrosis. The good news is that the NASH market is expected to reach between $20 to $30 billion in the coming years. It is a large market for plenty of players in this space. The other endpoints are important as well, but in a competitive market such as NASH, fibrosis reduction will make the difference in terms of more sales. This is just an important factor to keep in mind.
- [By ]
Heres what we wrote: With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The companys programs with GR-MD-02 are focusing on NASH treatment in individuals with advanced fibrosis and cirrhosis. As we mentioned before, Genfit (OTCPK:GNFTF) and Intercept (ICPT) are targeting what can be termed as the sweet spot of the NASH spectrum. Galecctin is one of the few companies targeting advanced stage of the disease. This makes it both an interesting and at the same time risky bet in the NASH space.